Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

875 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Among authors: park jo. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Lee J, et al. Among authors: park kw, park ys, park jo, park sh, park k. Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90. doi: 10.1007/s00280-004-0837-7. Epub 2004 Jul 10. Cancer Chemother Pharmacol. 2004. PMID: 15248028 Clinical Trial.
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K. Park SH, et al. Among authors: park jo, park ch, park k, park j. Am J Clin Oncol. 2004 Oct;27(5):477-80. doi: 10.1097/01.coc.0000136018.81814.79. Am J Clin Oncol. 2004. PMID: 15596914 Clinical Trial.
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Lim DH, et al. Among authors: park bb, park kw, park ys, park jo, park k. Cancer Chemother Pharmacol. 2005 Jul;56(1):10-4. doi: 10.1007/s00280-004-0963-2. Epub 2005 Mar 22. Cancer Chemother Pharmacol. 2005. PMID: 15782313 Clinical Trial.
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K. Lee J, et al. Among authors: park yh, park kw, park ys, park jo, park k. Eur J Cancer. 2005 Jul;41(10):1402-8. doi: 10.1016/j.ejca.2005.03.010. Eur J Cancer. 2005. PMID: 15963893
A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY. Uhm JE, et al. Among authors: park ys, park jo, park sh. Cancer Chemother Pharmacol. 2009 Apr;63(5):929-35. doi: 10.1007/s00280-008-0817-4. Epub 2008 Aug 23. Cancer Chemother Pharmacol. 2009. PMID: 18726098 Clinical Trial.
875 results